Fetal muscle gene transfer is not enhanced by an RGD capsid modification to high-capacity adenoviral vectors

被引:17
|
作者
Bilbao, R
Reay, DP
Hughes, T
Biermann, V
Volpers, C
Goldberg, L
Bergelson, J
Kochanek, S
Clemens, PR
机构
[1] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15213 USA
[2] Univ Cologne, Ctr Mol Med, Cologne, Germany
[3] Childrens Hosp Philadelphia, Div Infect Dis & Immunol, Philadelphia, PA 19104 USA
[4] Dept Vet Affairs Med Ctr, Neurol Serv, Pittsburgh, PA USA
关键词
in utero; high-capacity adenoviral vector; muscle; RGD; targeting;
D O I
10.1038/sj.gt.3302084
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
High levels of alpha(v) integrin expression by fetal muscle suggested that vector re-targeting to integrins could enhance adenoviral vector-mediated transduction, thereby increasing safety and efficacy of muscle gene transfer in utero. High-capacity adenoviral (HC-Ad) vectors modified by an Arg-Gly-Asp (RGD) peptide motif in the HI loop of the adenoviral fiber (RGD-HC-Ad) have demonstrated efficient gene transfer through binding to alpha(v) integrins. To test integrin targeting of HC-Ad vectors for fetal muscle gene transfer, we compared unmodified and RGD-modified HC-Ad vectors. In vivo, unmodified HC-Ad vector transduced fetal mouse muscle with four-fold higher efficiency compared to RGD-HC-Ad vector. Confirming that the difference was due to muscle cell autonomous factors and not mechanical barriers, transduction of primary myogenic cells isolated from murine fetal muscle in vitro demonstrated a three-fold better transduction by HC-Ad vector than by RGD-HC-Ad vector. We hypothesized that the high expression level of coxsackievirus and adenovirus receptor (CAR), demonstrated in fetal muscle cells both in vitro and in vivo, was the crucial variable influencing the relative transduction efficiencies of HC-Ad and RGD-HC-Ad vectors. To explore this further, we studied transduction by HC-Ad and RGD-HC-Ad vectors in paired cell lines that expressed alpha(v) integrins and differed only by the presence or absence of CAR expression. The results increase our understanding of factors that will be important for retargeting HC-Ad vectors to enhance gene transfer to fetal muscle.
引用
收藏
页码:1821 / 1829
页数:9
相关论文
共 50 条
  • [31] Selective depletion or blockade of Kupffer cells leads to enhanced and prolonged hepatic transgene expression using high-capacity Adenoviral vectors
    Schiedner, G
    Hertel, S
    Johnston, M
    Dries, V
    van Rooijen, N
    Kochanek, S
    MOLECULAR THERAPY, 2003, 7 (01) : 35 - 43
  • [32] Effective high-capacity gutless adenoviral vectors mediate transgene expression in human glioma cells
    Candolfi, Marianela
    Curtin, James F.
    Xiong, Wei-Dong
    Kroeger, Kurt M.
    Liu, Chunyan
    Rentsendorj, Altan
    Agadjanian, Hasmik
    Medina-Kauwe, Lali
    Palmer, Donna
    Ng, Philip
    Lowenstein, Pedro R.
    Castro, Maria G.
    MOLECULAR THERAPY, 2006, 14 (03) : 371 - 381
  • [33] Gene transfer with a high-capacity adenovirus vector.
    Gilgenkrantz, H
    M S-MEDECINE SCIENCES, 1998, 14 (05): : 669 - 670
  • [34] Delivery of the SCN1A into the brain using High-Capacity Adenoviral vectors for the treatment of Dravet Syndrome
    Mora-Jimenez, L.
    Lumbreras, S.
    Valencia, M.
    Puerta, E.
    Sanchez-Carpintero, R.
    Nicolas-Apesteguia, M. J.
    Besne, G.
    Artieda, J.
    Arrieta, S.
    Tonessen, J.
    Miguelez, C.
    Sola, N.
    Hernandez-Alcoceba, R.
    Ricobaraza, A.
    HUMAN GENE THERAPY, 2019, 30 (11) : A97 - A97
  • [35] High-capacity adenoviral vectors with controlled expression of interleukin 12 as a new strategy against pediatric osteosarcoma
    Zalacain, Marta
    Laspieda, Virginia
    Martinez-Velez, Naiara
    Marrodan, Lucia
    Bunuales, Maria
    Gonzalez-Huarriz, Marisol
    Varela, Maider
    Puigdelloses, Montserrat
    Gonzalez-Aparicio, Manuela
    Maria Alonso, Marta
    Hernandez, Ruben
    Patino-Garcia, Ana
    CANCER RESEARCH, 2019, 79 (13)
  • [36] Molecular design of high-capacity adenoviral vectors as large transgene carriers exemplified by von Willebrand factor
    Klein, L. M.
    Solanki, M.
    Portier, I.
    Vandelanotte, S.
    Zhang, W.
    Ehrke-Schulz, E.
    Vanhoorelbeke, K.
    De Meyer, S. F.
    Ehrhardt, A.
    HUMAN GENE THERAPY, 2024, 35 (3-4) : A251 - A251
  • [37] Persistence of High-Capacity Adenoviral Vectors as Replication-Defective Monomeric Genomes In Vitro and in Murine Liver
    Jager, Lorenz
    Ehrhardt, Anja
    HUMAN GENE THERAPY, 2009, 20 (08) : 883 - 896
  • [38] Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors
    Chuah, MKL
    Schiedner, G
    Thorrez, L
    Brown, B
    Johnston, M
    Gillijns, V
    Hertel, S
    Van Rooijen, N
    Lillicrap, D
    Collen, D
    VandenDriessche, T
    Kochanek, S
    BLOOD, 2003, 101 (05) : 1734 - 1743
  • [39] Intracerebral transplantation and successful integration of astrocytes following genetic modification with a high-capacity adenoviral vector
    Arnhold, S
    Kreppel, F
    Kandirali, S
    Lenartz, D
    Klinz, FJ
    Sturm, V
    Kochanek, S
    Andressen, C
    Addicks, K
    CELL TRANSPLANTATION, 2002, 11 (07) : 663 - 670
  • [40] Systemic delivery of a high-capacity adenoviral vector expressing mCTLA41g improves skeletal muscle gene therapy
    Clemens, PR
    Jiang, ZL
    Kochanek, S
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2002, 199 : S1 - S1